Gilead Prezista+9350 Study

A Phase 3b, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir Plus Two Fully Active Nucleoside Reverse Transcriptase Inhibitors in HIV-1 Infected, Antiretroviral Treatment-Naïve and –Experienced Adults with No Darunavir Resistance-associated Mutations. (Open for enrollment).